Answers are grounded in this paper and cite their sources.
Multinational comparative analysis shows no significant survival benefit of liver transplantation over systemic therapies for neuroendocrine liver metastasis patients meeting Milan criteria.
Background Liver transplantation (LT) is considered a potential curative option for neuroendocrine liver metastases (NELM), yet its survival benefit compared to modern systemic therapies (ST) remains a subject of debate. Aims To rigorously compare overall survival (OS) between LT and ST in patients with NELM who met the Milan criteria, utilizing a large international database. Methods A multinational, 17-center retrospective cohort study was conducted involving specialized hepatobiliary centers. Patients with pathology-proven NELM undergoing either LT or ST as their primary liver-directed strategy were included. To minimize selection bias, a 1:1 propensity score matching (PSM) was performed based on key prognostic variables: age, primary tumor location, tumor grade, and presence of extrahepatic disease. The primary outcome was OS calculated from the date of NELM diagnosis. Results From a total cohort of 1,281 patients, 81 in the LT group and 99 in the ST group met the Milan criteria. PSM resulted in a balanced cohort of 136 patients (68 per group). In the matched analysis, the median OS was 215 months (95% CI: 176–NA) for LT compared to 166 months (95% CI: 106–NA) for ST. This difference was not statistically significant (Hazard Ratio [HR]: 1.24; 95% CI: 0.65-2.36; p=0.5). The 10-year OS probability was 67% for LT and 57% for ST. Subgroup analyses, including stratification by Ki-67 index (<10%) and exclusion of 90-day mortality, confirmed no significant survival advantage for the transplant cohort. Conclusion In this large multicenter analysis, LT did not demonstrate a statistically significant survival benefit over contemporary systemic therapies for patients meeting Milan criteria. While LT remains a valid option for specific refractory cases, these findings suggest that non-surgical management with modern systemic agents offers comparable long-term outcomes for well-selected patients.
No takes yet. Share an insight, caveat, or question.
Eshmuminov et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: